GO321 for advanced solid tumors
Part of Cancer clinical trials.
This study tests an experimental drug called GO321 in people with advanced solid tumors that have stopped responding to standard treatments or for which no standard treatment exists. The drug is given either as an injection into the tumor or into the abdomen to treat fluid buildup caused by cancer (malignant ascites). This trial aims to see if GO321 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (like ovarian or gastrointestinal cancer) that has not improved with standard treatments, or no standard treatment is available.
- If you have fluid buildup in your belly from cancer, it must have returned within 4 weeks after at least one previous local treatment (like draining the fluid).
- If the drug is given directly into a tumor, you must have at least one tumor that can be safely injected, either felt by hand or seen on imaging, and it should be at least 1 cm across.
- You are generally well enough to be up and about (ECOG score 2 or less), and your life expectancy is at least 3 months.
- Your blood and organ function must be within certain limits (like adequate white blood cell counts, liver and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GO306 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have certain cancers like breast, bladder, colorectal, kidney, ovarian, or neuroendocrine tumors, and you have malignant ascites (fluid buildup in the belly) that needs treatment.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.